1. Home
  2. DETX vs PASG Comparison

DETX vs PASG Comparison

Compare DETX & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Liberty Defense Holdings Ltd. Common Shares

DETX

Liberty Defense Holdings Ltd. Common Shares

N/A

Current Price

$2.14

Market Cap

14.8M

ML Signal

N/A

Logo Passage Bio Inc.

PASG

Passage Bio Inc.

HOLD

Current Price

$4.61

Market Cap

14.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DETX
PASG
Founded
N/A
2017
Country
United States
United States
Employees
N/A
27
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
14.8M
14.8M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
DETX
PASG
Price
$2.14
$4.61
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
★ $14.00
AVG Volume (30 Days)
★ 33.6K
25.1K
Earning Date
N/A
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$3.29
52 Week High
$4.25
$20.00

Technical Indicators

Market Signals
Indicator
DETX
PASG
Relative Strength Index (RSI) 36.75 45.33
Support Level $1.97 $4.27
Resistance Level $2.43 $4.95
Average True Range (ATR) 0.24 0.26
MACD 0.02 -0.03
Stochastic Oscillator 38.78 15.83

Price Performance

Historical Comparison
DETX
PASG

About DETX Liberty Defense Holdings Ltd. Common Shares

Liberty Defense Holdings Ltd is engaged in the development and commercialization of security detection technologies such as airports, stadiums, schools, and more. The company's Hexwave product utilizes millimeter wave technology and Advanced 3D imaging to detect concealed threats. In addition to HEXWAVE, the company has licensed High-Definition Advanced Imaging Technology (HD-AIT) for body and shoe scanning. The Company operates through three distinct segments: Corporate, HEXWAVE, and Contract. The company generates the majority of its revenue from the Contract segment. Geographically, the company generates the majority of its revenue from the United States.

About PASG Passage Bio Inc.

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

Share on Social Networks: